BIBLIOGRAPHY

Agrawal, S., Ashokraj, Y., Bharatam, P.V., Pillai, O. and Panchagnula, R., 2004. Solid-state characterization of rifampicin samples and its biopharmaceutic relevance. *Eur. J. Pharm. Sci.* 22, 127-144.

Bain, D.F., Munday, D.L. and Cox, P.J., 1998. Evaluation of biodegradable rifampicin-bearing microsphere formulations using a stability-indicating high-performance liquid chromatographic assay. *Eur. J. Pharm. Sci.* 7, 57-65.

Bardou, F., Raynaud, C., Ramos, C., Lanéelle, A. and Lanéelle, G., 1998. Mechanism of isoniazid uptake in *Mycobacterium tuberculosis*. *Microbiology* 144, 2539-2544.

Bisgaard, H., 1998. Targeting drugs to the respiratory tract. *Res. Immunol.* 149, 229-331.

Blanc, D.C. and Nunn, P., 1999. *Incentives and disincentives for new anti-tuberculosis drug development*. Geneva, World Health Organization. Available online at : http//www.who.int.tdr.

Boer, A.H., Gjaltema, D., Hagedoorn, P., Schaller, M., Witt, W. and Frijlink, H.W., 2002. Design and application of a new modular adapter for laser diffraction characterization of inhalation aerosols. *Int. J. Pharm.* 249, 233-245.

Bosquillon, C., Lombry, C., Préat, V. and Vanbever, R., 2001. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. *J. Control. Release* 70, 329-339.

Bosquillon, C., Rouxhet, P.G., Ahimou, F., Simon, D., Culot, C., Préat, V. and Vanbever, R., 2004. Aerosolization properties, surface composition and physical state of spray-dried protein protein powders. *J. Control. Release* 99, 357-367.

Brewer, G.A., 1977. Isoniazid. In : Florey, K. (Ed.), *Analytical profile of drug substances Volume 6.* New York : Academic Press. pp. 183-258.

British Pharmaceutical Conference, 2002. Patient and industry views on inhalers. *P.J.* 269, 536-537.

British Pharmacopoeia, 1998. Aerodynamic Assessment of Fine Particles. Her Majesty's Stationery Office, Appendix XII F.

Calleri, E., Lorenzi, E.D., Furlanetto, S., Massolini, G. and Caccialanza, G., 2002. Validation of a RP-LC method for the simultaneous determination of isoniazid, pyrazinamide and rifampicin in a pharmaceutical formulation. *J. Pharmaceut. Biomed.* 29, 1089-1096.

Campbell, E.A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A. and Darst, S.A., Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. *Cell* 104, 901-912.

Challoner, P.B., 2002. Chapter 15 Aerosol delivery of antibiotics. In : *Annual Reports in Medicinal Chemistry. s.l.*, Elsevier Sciences. pp. 149-158.

Chan H.K. and Chew, N.Y.K., 2003. Novel alternative methods for the delivery of drugs for the treatment of asthma. *Adv. Drug Deliv. Rev.* 55, 793-805.

Coban, A.Y., Birinci, A., Ekinci, B. and Durupinar, B., 2004. Drug susceptibility testing of *Mycobacterium tuberculosis* by the broth microdilution method with 7H9 broth. *Mem. Inst. Oswaldo Cruz* 99(1), 111-113.

Cortes, F.V. and Caekenberghe, D.V., 1997. Glassification and its applications. *Ann Med. Milit. Belg.* 11(1), 17-23.

Deol, P. and Khuller, G.K., 1997. Lung specific stealth liposomes : stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. *Biochim. Biophys. Acta* 1334, 161-172.

Dhople, A.M., Dhople, A.A. and Ibanez, M.A., 1997. Comparative *in vitro* activities of rifamycin analogues against rifampin-sensitive and rifampin-resistant *Mycobacterium tuberculosis. Int. J. Antimicrob. Ag.* 8, 209-214.

Drobniewski, F., 2002. Antimicrobial susceptibility testing of *Mycobacterium tuberculosis*. Eucast Disscussion Document E. DIS 8.1 December 2001. Available online at : http://www.escmid.org/seviware/Script/ SvFiles.asp? Ref=312.

Dutt, M. and Khuller, G.K., 2001a. Liposome and PLG microparticles as sustained release antitubercular drug carriers-an *in vitro-in vivo* study. *Int. J. Antimicrob. Ag.* 18, 245-252.

Dutt, M. and Khuller, G.K., 2001b. Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. *Int. J. Antimicrob. Ag.* 17, 115-122.

European Pharmacopeia, 2002. European Directorate for the Quality of Medicine, Strasbourg, France.

Falk, R., Randolph, T.W., Meyer, J.D., Kelly. R.M. and Manning, M.C., 1997. Controlled release of ionic compounds from poly(L-lactide) microspheres produced by precipitation with a compressed antisolvent. *J. Control. Release* 44, 77-85.

Flament, M.P., Leterme, P. and Gayot, A., 2004. The influence of carrier roughness on adhesion, content uniformity and the *in vitro* deposition of terbutaline sulphate from dry powder inhalers. *Int. J. Pharm.* 275, 201-209.

French, D., Edwards, D.A. and Niven, R.W., 1996. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. *J. Aerosol Sci.* 5, 769-783.

Gallo, G.C. and Radaelli, P., 1976. Rifampicin. In : Florey, K. (Ed.), *Analytical profile of drug substances Volume 5*. New York : Academic Press. pp. 467-513.

Genium Publishing Corporation, 1999. *Genium's Handbook of Safty, Health, and Environmental Data for common hazardous substances*. New York, McGraw-Hill.

Ghanta, J., Shen, C.L., Kiessling, L.L. and Murphy, R.M., A strategy for designing inhibitors of β-amyloid toxicity. *J. Biol Chem.* 271(47), 29525-29528.

Gilani, K. Najafabadi, A.R., Barghi, M. and Rafiee-Tehrani, M., 2004. Aerosolisation of beclomethasone dipropionate using spray dried lactose/polyethylene glycol carriers. *Eur. J. Pharm. Biopharm.* 58, 595-606.

Golfinopoulos, S.K., Kostopoulou, M.N. and Lekkas, T.D., 1998. Volatile halogenated organics in the water supply system in Athens, Greece. *Water Res.* 32 (6), 1811-1818.

Groves, M.J., 1997. BCG : the past, present and future of a tuberculosis vaccine. *J. Pharm. Pharmacol.* 49 (suppl. 1), 7-15.

Grange, J.M. and Zumla, A., 2002. Chapter 57 Tuberculosis. In Section 1 Underlying factor in tropical medicine. *s.l., s.n.*

Gürsoy, A., Kut, E. and Özkırımlı, S., 2004. Co-encapsulation of isoniazid and rifampicin in liposomes and characterization of liposomes by derivative spectroscopy. *Int. J. Pharm.* 271, 115-123.

Hallworth, G.W. and Westmoreland, D.G., 1987. The twin impinger : a simple device for assessing the delivery of drugs from metered dose pressurized aerosol inhalers. *J. Pharm. Pharmacol.* 39, 966-972.

Harjunen, P., Lehto, V., Martimo, K., Suihko, E., Lankinen, T., Paronen, P. and Järvinen, K., 2002. Lactose modifications enhance its drug performance in the novel multiple dose Taifun® DPI. *Eur. J. Pharm. Sci.* 16, 313-321.

Hickey, A.J., 1992. Pharmaceutical Inhalation Aerosol Technology. Marcel Dekker, New York.

Higashiyama, T., 2002. Novel functions and applications of trehalose. *Pure Appl. Chem.* 74(7), 1263-1269.

ICH, 1996. Guidance for Industry Q2B Validation of Analytical Procedures : Methodology. Center for Drug Evaluation and Research (CDER), Rockville, MD, USA.

Khuller, G.K. and Pandey, R., 2003. Sustained release drug delivery systems in management of tuberculosis. *Indian J. Chest Dis. Allied Sci.* 45, 229-230.

Kirk, S.M., Mazurek, G.H., Callister, S.M., Moore, A.V. and Schell, R.F., 1998a. *Mycobacterium tuberculosis* susceptibility results in 24 hours by using flow cytometry. *CMNEEJ.* 20, 83-87.

Kirk, S.M. Schell, R.F., Moore, A.V., Callister, S.M. and Mazurek, G.H., 1998b. Flow cytometric testing of susceptibilities of *Mycobacterium tuberculosis* isolates to ethambutol, isoniazid, and rifampin in 24 hours. *J. Clin. Microbiol.* 36 (6), 1568-1573.

Kostopoulou, M.N., Golfinopoulos, S.K., Nikolaou, A.D., Xilourgidis, N.K. and Lekkas, T.D., 2000. Volatile organic compounds in the surface waters of Northern Greece. *Chemosphere* 40, 527-532.

Larhrib, H., Martin, G.P., Prime, D. and Marriott, C., 2003a. Characterisation and deposition studies of engineered lactose crystals with potential for use as a carrier for aerosolised salbutamol sulfate from dry powder inhalers. *Eur. J. Pharm. Sci.* 19, 211-221.

Larhrib, H., Martin, G.P., Marriott, C. and Prime, D., 2003b. The influence of carrier and drug morphology on drug delivery from dry powder formulations. *Int. J. pharm.* 257, 283-296.

Leite, C.Q.F., Beretta, A.L.R.Z., Anno, I.S. and Telles, M.A.S., 2000. Standartization of broth microdilution method for *Mycobacterium tuberculosis*. *Mem. Inst. Oswaldo Cruz* 95(1), 127-129.

Liu, Y., Tsapis, N. and Edwards, D.A., 2003. Investigating sustained-release nanoparticles for pulmonary drug delivery. Available online at : http:// www.eduprograms.deas.harvard.edu/ reu03_papers/Liu.Y.FinReport03.pdf .

Louey, M.D., Razia, S. and Stewart, P.J., 2003. Influence of physico-chemical carrier properties on the *in vitro* aerosol deposition from interactive mixtures. *Int. J. Pharm.* 252, 87-98.

Malcolmson, R.J. and Embleton, J.K., 1998. Dry powder formulations for pulmonary delivery. *PSTT.* 1(9), 394-398.

McClatchy, J.K., 1971. Mechanism of action of isoniazid on *Mycobacterium bovis* strain BCG. *Infect. Immun.* 1971, 530-534.

Miller, D.P., Pablo, J.J. and Corti, H., 1997. Thermophysical properties of trehalose and its concentrated aqueous solutions. *Pharm. Res.* 14(5), 578-590.

Mitchell, J.P., Costa, P.A. and Waters, S., 1988. An assessment of an Andersen Mark-II cascade impactor. *J. Aerosol. Sci.* 19(2), 213-221.

Mitchell, J.P. and Nagel, M.W., 2004. Particle size analysis of aerosols from medicinal inhalers. *KONA* 22, 32-65.

Mitchell, J.P., Nagel, M.W., Wiersema, K.J. and Doyle, C.C., 2003. Aerodynamic particle size analysis of aerosols from pressurized metered dose inhalers : comparison of Andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 aerodynamic particle sizer aerosol spectrometer. *AAPS PharmSciTech.* 4(4), 1-9. Article 54 (http://www.aapspharmscitech.org).

Mohamad, S., Ibrahim, P. and Sadikun, A., 2004. Susceptibility of *Mycobacterium tuberculosis* to isoniazid and its derivatives, 1-isonicotinyl-2-nonanoyl hydrazine : investigation at cellular level. *Tuberculosis* 84, 56-62.

Mori, H., Mio, H., Kano, J. and Saito, F., 2004. Ball mill simulation in wet griding using a tumbling mill and its correlation to grinding rate. *Powder Technol.* 143-144, 230-239.

Müller, M., Mackeben, S. and Müller-Goymann, C.C., 2004. Physicochemical characterization of liposomes with encapsulated local anaesthetics. *Int. J. Pharm.* 274, 139-148.

Norden, M.A., Kurzynski, T.A. Bownds, S.E., Callister, S.M. and Schell, R.F., 1995. Rapid susceptibility testing of *Mycobacterium tuberculosis* (H37Ra) by flow cytometry. *J. Clin. Microbiol.* 33 (5), 1231-1237.

Okamoto, H., Todo, H., Iida, K. and Danjo, K., 2002. Dry powders for pulmonary delivery of peptides and proteins. *KONA* 20, 71-83.

Opanasopit, P., Higuchi, Y., Kawakami, S., Yamashita, F., Nishikawa, M. and Hashida, M., 2001. Involvement of serum mannan binding proteins and mannose receptors in uptake of mannosylated liposomes by macrophages. *Biochim. Biophys. Acta* 1511, 134-145.

Panchagnula, R. and Agrawal, S., 2004. Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin. *Int. J. Pharm.* 271, 1-4.

Philip V.A., Mehta, R.C., Mazumder, M.K. and DeLuca, P.P., 1997. Effect of surface treatment on the respirable fractions of PLGA microspheres formulated for dry powder inhalers. *Int. J. Pharm.* 151, 165-174.

Platz, R.M., Patton, J.S., Foster, L. and Eljamal, M., 2003. Spray drying of macromolecules to produce inhalable dry powder. Pharmaceutical Patents. Available online at : http://www.pharmacast.com/Patents/Y2003/June2003/6582728_SprayDrying062403.htm.

Rastogi, N., Goh, K.S., Berchel, M. and Bryskier, A., 2000. Activity of rifapentine and its metabolite 25-*O*-desacetylrifapentine compared with rifampicin and rifabutin against *Mycobacterium tuberciulosis*, *Mycobacterium africanum*, *Mycobacterium bovis* and *M. bovis* BCG. *J. Antimicrob. Chemoth.* 46, 565-570.

Raynolds, J. E. F., (Ed.), 1993. *Martindale The Extra Pharmacopoeia.* 3rd ed. London, The Pharmaceutical Press.

Reichman, L.B. and Hershfield, E.H., (Ed.), 2000. Tuberculosis A Comprehensive International Approach. 2nd ed., Marcel Dekker, New York.

Reverchon, E., Macro, I.D. and Porta, G.D., 2002. Rifampicin microparticles production by supercritical antisolvent precipitation. *Int. J. Pharm.* 243, 83-91.

Roos, Y.H., 2002. Importance of glass transition and water activity to spray drying and stability of dairy powders. *Lait* 82, 475-484.

Sethuraman, V.V. and Hickey, A.J., 2001. Evaluation of preseparator performance for the 8-stage nonviable Andersen impactor. *AAPSPharmSciTech.* 2(1), 1-9. Article 4 (http://www.aapspharmsci.org).

Sethuraman, V.V. and Hickey, A.J., 2002. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug. *AAPSPharmSciTech.* 3(4), 1-10. Article 28 (http://www.aapspharmsci.org).

Sham, J.O.H., Zhang, Y., Finlay, W.H., Roa, W.H. and Löbenberg, R., 2004. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. *Int. J. Pharm.* 269, 457-467.

Sharma, R., Saxena, D., Dwivedi, A.K. and Misra, A., 2001. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. *Pharm. Res.* 18(10), 1405-1410.

Shekunov, B.Y., Feeley, J.C., Chow, A.H.L., Tong, H.H.Y. and York, P., 2003. *J. Aerosol Sci.* 34, 553-568.

Smith, I.J. and Parry-Billings, M., 2003. The inhalers of the future ? A review of dry powder devices on the market today. *Pulm. Pharmacol. Ther.* 16, 79-95.

Srichana, T., 1998. *A study of some factors affecting the deposition of drug and excipients following aerosolization of dry powders.* PhD thesis. Submitted at University of London, Department of Pharmacy, King's College London, London, UK. (Unpublished)

Srichana, T. Suedee, R. and Reanmongkol, W., 2001. Cyclodextrin as a potential drug carrier in salbutamol dry powder aerosols : the *in-vitro* deposition and toxicity studies of the complexes. *Resp. Med.* 95, 513-519.

Srichana, T., Suedee, R. and Srisudjai, P., 2003. Application of spectrofluorometry for evaluation of dry powder inhalers *in vitro*. *Pharmazie* 58, 125-129.

Stahlberg, H., Kutejová, E., Suda, K., Wolpensinger, B., Lustig, A., Schatz, G., Engel, A. and Suzuki, C.K., 1999. Mitocondrial lon og Saccharomyces cerevisiae is a ring-shaped protease with seven flexible subunits. *Proc. Natl. Acad. Sci. USA* 96, 6787-6790.

Steckel, H. and Bolzen, N., 2004. Alternative sugars as potential carriers for dry powder inhalations. *Int. J. Pharm.* 270, 297-306.

Steckel, H. and Brandes, H.G., 2004. A novel spray-drying technique to produce low density particles for pulmonary delivery. *Int. J. Pharm.* 278, 187-195.

Steckel, H., Markefka, P., teWierik, H. and Kammelar, R., 2004. Functionality testing of inhalation grade lactose. *Eur. J. Pharm. Biopharm.* 57, 495-505.

Storey, S., 2004. Tuberculosis-a general introduction. *P. J.* 273, 289-291.

Suarez, S. and Hickey, A., 2000. Drug properties affecting aerosol behavior. *Respir. Care*. 45(6), 652-666.

Suarez, S., O'Hara, P. Kazantseva, M. Newcomer, C.E., Hopfer, R., McMurray, D.N. and Hickey, A.J., 2001. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis : screening in an infectious disease model. *Pharm. Res.* 18(9), 1315-1319.

Tee, S.K., Marriott, C., Zeng, X.M. and Martin, G.P., 2000. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate. *Int. J. Pharm.* 208, 111-123.

Tsapis, N. Bennett, D., Jackson, B., Weitz, D.A. and Edwards, D.A., 2002. Trojan particles : large porous carriers of nanoparticles for drug delivery. *PNAS* 99(19), 12001-12005.

Tsapis, N., Bennett, D., O'Driscoll, K., Shea, K., Lipp, M.M., Fu, K., Clarke, R.W., Deaver, D., Yamins, D., Wright, J., Peloquin, C.A., Weitz, D.A. and Edwards, D.A., 2003. Direct lung delivery of para-aminosalicylic acid by aerosol particles. *Tuberculosis* 83, 379-385.

US Pharmacopeia 24-NF19, 2000. US Pharmacopeial Convention, Inc., Rockville, MD, USA.

US Pharmacopeia 28-NF23, 2003. US Pharmacopeial Convention, Inc., Rockville, MD, USA.

Vyas, S.P., Kannan, M.E., Jain, S., Mishra, V. and Singh, P., 2004. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. *Int. J. Pharm.* 269, 37-49.

Wade, A. and Weller, P. (Ed.)., 1994. *Handbook of Pharmaceutical Excipients.* 2nd ed. London, The Pharmaceutical Press.

White, R.J., Lancini, G.C. and Silvestri, L.G., 1971. Mechanism of action of rifampicin on Mycobacterium smegmatis. *J. Bacteriol.* 108, 737-741.

Wiens, T., Redelmeier, T. and Av-Gay, Y., 2004. Development of liposome formulation of ethambutol. *Antimicrob. Agents Ch.* 48(5), 1887-1888.

Winden, E.C.A. and Crommelin, D.J.A., 1999. Short term stability of freeze-dried, lyoprotected liposomes. *J. Control. Release* 58, 69-86.